ALLMedicine™ Alopecia Center

Dec 1st, 2022 - Despite the widespread use of nutritional supplements and dietary interventions for treating hair loss, the safety and effectiveness of available products remain unclear. To evaluate and compile the findings of all dietary and nutritional interven...

Dec 1st, 2022 - Alopecia areata is an autoimmune condition that causes non-scarring hair loss. To date, there is no single cure and treatment remains challenging. To evaluate the efficacy of Jessener solution versus intralesional steroid in treatment of Alopecia ...

Nov 30th, 2022 - Hereditary hemochromatosis (HHC), a disorder of iron overload, presents with clinical phenotypic heterogeneity. Complications can be mitigated with early intervention. The association between HHC and alopecia areata (AA) is unknown. We report 4 pa...

Nov 30th, 2022 - Immune mechanisms are considered to be responsible for the pathogenesis of cicatricial alopecia in lichen planopilaris (LPP) and discoid lupus erythematosus (DLE) diseases. CD200 has an immunomodulatory function in hair follicles. The functions of...

Nov 29th, 2022 - Studies reporting the development and effectiveness of topical agents for alopecia are available. However, it was difficult to demonstrate a direct advantage of subcutaneous injection rather than topical application. Since existing articles lack i...

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

Oct 14th, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Oct 13th, 2022 - Aloe Vera is medicinal plant that has been used to treat skin problems since 1500 BC Many studies have shown that using Aloe Vera to treat various wounds such as psoriasis, mouth ulcers, diabetic ulcers herpes and bed sores has had positive effect...

Oct 13th, 2022 - The purpose of this study is to evaluate the efficacy and tolerability of squaric acid dibutylester (SADBE) in children and adolescents with alopecia areata (AA) and to evaluate effect of squaric acid dibutyl ester on patient-centered outcomes and...

Oct 5th, 2022 - Adult volunteers aged 22-45 years presenting with mild to moderate patterned hair loss will be screened for participation. Twenty subjects (10 males and 10 females) meeting the inclusion/exclusion criteria will be recruited to participate. Prior t...

Oct 5th, 2022 - PRIMARY OBJECTIVE: I. Safety, defined as timely engraftment (the collective establishment of a persistent absolute neutrophil count of at least 500 cells/mm^3 and platelet count of 20,000 cells/mm^3 without transfusion for 3 consecutive measuremen...

Nov 22nd, 2022 - GlaxoSmithKline (GSK) plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at le...

Nov 21st, 2022 - AMSTERDAM — In an effort to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended limiting the indicat...

Nov 15th, 2022 - The addition of eganelisib (IPI-549) to atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) demonstrated evidence of a long-term progression-free survival (PFS) benefit when used as first-line treatment in patients with metastatic triple-negati...

Nov 10th, 2022 - In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, of the Division of Gynecologic Oncology, Allegheny Health Network, and assistant professor of OBGYN at Drexel University, and Ali Amjad, MD, medical hematologic oncologi...

Nov 7th, 2022 - Belantamab mafodotin-blmf (Blenrep) did not generate a progression-free survival (PFS) benefit vs the combination of pomalidomide (Pomalyst) plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial (NCT04162...